Dr. Alfred Hansel

CEO at oncgnostics

As CEO Dr. Hansel is responsible for business development at oncgnostics. He has long-lasting experience in project management obtained while working at several universities in Germany and abroad as well as operative experience in industrial product development, sales and marketing.

The spin-off of oncgnostics is based on his research as well as works of a project group at the university hospital, which he has led.

oncgnostics

Title: Epigenetic markers in cancer diagnostics

  • Basics on epigenetic markers
  • Identification and diagnostic testing of markers
  • The current use of epigenetic markers in diagnostics